Natera And BGI Genomics Announce Commercial Launch Of The BGI Natera Signatera Assay In China

Natera, Inc., a pioneer and global leader in cell-free DNA (cfDNA) testing, and BGI Genomics Co., Ltd., (300676.SZ), one of the world’s leading genomics companies, today announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China. Natera’s Signatera® assay, now offered in partnership with BGI,1 has been utilized in numerous clinical studies across non-small cell lung, bladder, breast and colorectal cancers, to identify molecular residual disease (MRD) up to two years earlier than standard imaging. The test is now available in China under the Chinese brand name "华见微®–肿瘤MRD定制化检测" – 华见微 (Hua Jian Wei for short). "We’re excited to bring this revolutionary technology to clinicians and patients in China," said John Fesko, chief business officer at Natera. "Partnering with BGI also enables Natera to offer our pharma partners truly global clinical trial services." In March 2019, Natera and BGI Genomics entered into a partnership to commercialize Natera’s Signatera test in China,1 and after two years of technology transfers and validation, the BGI/Natera Signatera Assay (华见微) is now officially available in the country. The assay can help facilitate innovative trial design and enable biopharmaceutical researchers to make better informed and more timely decisions. Pharmaceutical companies can access this assay in China through the BGI-Natera partnership, which offers unique opportunities for companion diagnostic registration in both China and the U.S. "BGI is committed to promoting precision medicine and cancer prevention with cutting-edge technologies. Signatera can detect recurrence earlier and help clinicians optimize treatment decisions, thus bringing greater survival benefits for patients. In partnership with Natera, we are pleased to introduce Signatera into China and provide this innovative technology that incorporates MGI sequencing platforms for clinical oncology and drug development in a reliable and affordable manner," said Shida Zhu, general manager of BGI Oncology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!